Natalie E. Simpson

Specific requirement of the chromatin modifier mSin3B in cell cycle exit and cellular differentiation

Gregory David, Kathryn B. Grandinetti, Patricia M. Finnerty et al. · Proceedings of the National Academy of Sciences · 2008 · 122 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Emily Y. Jen, Xin Gao, Liang Li et al. · Clinical Cancer Research · 2019 · 91 citations

Medicine, Oncology, Pharmacology +13

An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates

Haleh Saber, Natalie E. Simpson, Tiffany K. Ricks et al. · Regulatory Toxicology and Pharmacology · 2019 · 90 citations

Pharmacy, Oncology, Toxicology +14

Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype

Natalie E. Simpson, Volodymyr Tryndyak, Marta Pogribna et al. · Epigenetics · 2012 · 81 citations · Full text

Medicine, Cancer Biology, Oncology +17

An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression

Natalie E. Simpson, Volodymyr Tryndyak, Frederick A. Beland et al. · Breast Cancer Research and Treatment · 2011 · 70 citations

Medicine, Biochemistry, Oncology +16